2016
Benefits of continuous isoniazid preventive therapy may outweigh resistance risks in a declining tuberculosis/HIV coepidemic
Kunkel A, Crawford FW, Shepherd J, Cohen T. Benefits of continuous isoniazid preventive therapy may outweigh resistance risks in a declining tuberculosis/HIV coepidemic. AIDS 2016, 30: 2715-2723. PMID: 27782966, PMCID: PMC5089846, DOI: 10.1097/qad.0000000000001235.Peer-Reviewed Original ResearchConceptsContinuous isoniazid preventive therapyIsoniazid preventive therapyIsoniazid-resistant tuberculosisTB epidemicPreventive therapyEffective TB treatmentLatent TB infectionTB drug resistanceTransmission dynamic modelTB infectionMortality benefitTB treatmentHIV controlHIV incidenceTB incidenceTB transmissionCase findingDrug resistanceIncidenceTuberculosisInitial benefitPLHIVHIVTherapyEpidemicTradeoffs in Introduction Policies for the Anti-Tuberculosis Drug Bedaquiline: A Model-Based Analysis
Kunkel A, Cobelens FG, Cohen T. Tradeoffs in Introduction Policies for the Anti-Tuberculosis Drug Bedaquiline: A Model-Based Analysis. PLOS Medicine 2016, 13: e1002142. PMID: 27727274, PMCID: PMC5058480, DOI: 10.1371/journal.pmed.1002142.Peer-Reviewed Original ResearchConceptsTreatment of tuberculosisMDR-TB treatmentTB treatmentSecondary casesDrug-resistant (XDR) TBResistance patternsLife expectancyMultidrug-resistant TB patientsDrug bedaquilineMDR-TB drugsAnti-tuberculosis drug bedaquilineCulture conversionMDR patientsTB patientsMortality benefitBedaquiline resistanceMedian timeRisk of resistanceTB drugsDecrease transmissionHypothetical cohortSources of heterogeneityDrug interactionsInitial cohortTime of initiation
2015
Evaluating the potential impact of enhancing HIV treatment and tuberculosis control programmes on the burden of tuberculosis
Chindelevitch L, Menzies NA, Pretorius C, Stover J, Salomon JA, Cohen T. Evaluating the potential impact of enhancing HIV treatment and tuberculosis control programmes on the burden of tuberculosis. Journal Of The Royal Society Interface 2015, 12: 20150146. PMID: 25878131, PMCID: PMC4424692, DOI: 10.1098/rsif.2015.0146.Peer-Reviewed Original ResearchConceptsAntiretroviral therapyTB incidenceTB burdenBurden of tuberculosisTuberculosis Control ProgrammePotential epidemiological impactART eligibilityMortality benefitTB programsHIV treatmentTB prevalenceTuberculosis incidenceEpidemiological impactART useProgram improvementHIVTreatment effectivenessIncidenceMortalityGreater reductionBurdenTBSaharan AfricaControl programsEligibility